Statistics for Akebia Therapeutics (id:5571 AKBA)

Valuation metrics

Market cap

390.54M

Enterprise value

466.27M

Trailing P/E (ttm)

-6.71

Forward P/E

-6.88

PEG ratio

-6.88

Price/Sales (ttm)

2.30

Price/Book (mrq)

-7.85

Enterprise Value/Revenue

2.74

Enterprise Value/EBITDA

105.73

Overview

Shares outstanding

218.18M

Float

198.27M

Shares short

14.84M

% Held by insiders

0.02%

% Held by institutions

0.27%

Average volume (10 days)

2.26M

Average volume (90 days)

Price summary

52-Week low

0.80

52-Week high

2.48

52-Week change

47.34%

Beta

0.73

50-Day moving average

1.52

200-Day moving average

1.41

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-27.07%

Operating margin

-33.41%

Operational effectiveness

Return on assets

-9.37%

Return on equity

169.78%

Income statement

Revenue (ttm)

0.83

Revenue per share (ttm)

0.83

Quarterly revenue growth (yoy)

Gross profit (ttm)

120.47M

EBITDA

4.41M

Net income to common (ttm)

-45,992,000.00

Diluted EPS (ttm)

-0.22

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

34.02M

Total cash per share (mrq)

0.16

Total debt (mrq)

103.20M

Total Debt/Equity (mrq)

-2.05

Current ratio (mrq)

152.40%

Book value per share (mrq)

-0.24

Cash flow

Cash flow statement

-38,501,000.00

Levered free cash flow (LFCF)

8.98M